(19)
(11) EP 1 208 847 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
14.02.2007 Bulletin 2007/07

(45) Mention of the grant of the patent:
27.09.2006 Bulletin 2006/39

(21) Application number: 01131018.2

(22) Date of filing: 29.07.1997
(51) International Patent Classification (IPC): 
A61K 38/13(2006.01)
A61P 37/00(2006.01)
 A61K 31/445(2006.01)
A61K 31/70(2006.01)

(54)

PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF TRANSPLANT REJECTION, AS WELL AS AUTOIMMUNE OR INFLAMMATORY CONDITIONS

PHARMAZEUTISCHE ZUSAMMENSETZUNGEN ZUR BEHANDLUNG DER TRANSPLANTATABSTOSSUNG SOWIE DER AUTOIMMUN- ODER ENTZÜNDLICHEN ZUSTÄNDE

COMPOSITIONS PHARMACEUTIQUES DESTINEES AU TRAITEMENT DES ETATS DE REJET DE GREFFE AINSI QUE DES MALADIES AUTOIMMUNES OU INFLAMMATOIRES

(84) Designated Contracting States:
AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
Designated Extension States:
RO SI

(30) Priority: 30.07.1996 GB 9615942
19.03.1997 GB 9705684

(43) Date of publication of application:
29.05.2002 Bulletin 2002/22

(62) Application number of the earlier application in accordance with Art. 76 EPC:
97937526.8 / 0956034

(73) Proprietors:
  • Novartis AG
    4056 Basel (CH)
    Designated Contracting States:
    BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE 
  • Novartis Pharma GmbH
    1230 Wien (AT)
    Designated Contracting States:
    AT 

(72) Inventors:
  • Zenke, Gerhard
    79618 Rheinfelden (DE)
  • Schuurman, Hendrik J.
    Charlestown Navy Yard, Charlestown MA (US)
  • Haeberlin, Barbara
    4142 Münchenstein (CH)
  • Meinzer, Armin
    79426 Buggingen (DE)

(74) Representative: Leon, Susanna Iris et al
Novartis AG Corporate Intellectual Property P.O. Box
4002 Basel
4002 Basel (CH)


(56) References cited: : 
EP-A- 0 401 747
WO-A-94/09010
 WO-A-00/67773
WO-A-97/25977
   
  • SHUURMAN H.J. ET AL: "SDZ-RAD, A NEW RAPAMYCIN DERIVATIVE. SYNERGISM WITH CYCLOSPORINE" TRANSPLANTATION, vol. 64, no. 1, 15 July 1997 (1997-07-15), pages 32-35, XP002048030
  • TU Y. ET AL: "The synergistic effects of cyclosporine, sirolimus, and brequinar on heart allograft survival in mice" TRANSPLANTATION, 1995, 59/2 (177-183), XP002048031 USA
  • SCHULER W. ET AL: "SDZ-RAD, A NEW RAPAMYCIN DERIVATIVE. Pharmacological properties in vitro and in vivo" TRANSPLANTATION, vol. 64, no. 1, 15 July 1997 (1997-07-15), pages 36-42, XP002048032
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).